@article{VoglLutzSchoenfelderetal.2015,
  author    = {Vogl, Silvia and Lutz, Roman W. and Sch{\"o}nfelder, Gilbert and Lutz, Werner K.},
  title     = {CYP2C9 genotype vs. metabolic phenotype for individual drug dosing - a correlation analysis using flurbiprofen as probe drug},
  series = {PLoS ONE},
  volume    = {10},
  journal   = {PLoS ONE},
  number    = {3},
  doi       = {10.1371/journal.pone.0120403},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148783},
  pages     = {e0120403},
  year      = {2015},
  abstract  = {Currently, genotyping of patients for polymorphic enzymes responsible for metabolic elimination is considered a possibility to adjust drug dose levels. For a patient to profit from this procedure, the interindividual differences in drug metabolism within one genotype should be smaller than those between different genotypes. We studied a large cohort of healthy young adults (283 subjects), correlating their CYP2C9 genotype to a simple phenotyping metric, using flurbiprofen as probe drug. Genotyping was conducted for CYP2C9*1, *2, *3. The urinary metabolic ratio MR (concentration of CYP2C9-dependent metabolite divided by concentration of flurbiprofen) determined two hours after flurbiprofen (8.75 mg) administration served as phenotyping metric. Linear statistical models correlating genotype and phenotype provided highly significant allele-specific MR estimates of 0.596 for the wild type allele CYP2C9*1, 0.405 for CYP2C9*2 (68 \% of wild type), and 0.113 for CYP2C9*3 (19 \% of wild type). If these estimates were used for flurbiprofen dose adjustment, taking 100 \% for genotype *1/*1, an average reduction to 84 \%, 60 \%, 68 \%, 43 \%, and 19\% would result for genotype *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively. Due to the large individual variation within genotypes with coefficients of variation >= 20\% and supposing the normal distribution, one in three individuals would be out of the average optimum dose by more than 20 \%, one in 20 would be 40\% off. Whether this problem also applies to other CYPs and other drugs has to be investigated case by case. Our data for the given example, however, puts the benefit of individual drug dosing to question, if it is exclusively based on genotype.},
  language  = {en}
}
@article{IlinKulmanovNersesyanetal.2015,
  author    = {Ilin, Alexander and Kulmanov, Murat and Nersesyan, Armen and Stopper, Helga},
  title     = {Genotoxic activity of the new pharmaceutical FS-1 in Salmonella/microsome test and mouse lymphoma L5178Y cells},
  series = {Journal of BUON},
  volume    = {20},
  journal   = {Journal of BUON},
  number    = {2},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-143769},
  pages     = {595-601},
  year      = {2015},
  abstract  = {Purpose: The purpose of this study was to determine possible genotoxic effects of a new very promising antibacterial/ antiviral drug FS-1. Methods: The drug was tested in TA98, TA100, TA102, TA 1535 and TA1537 strains of Salmonella (Ames test) with and without metabolic activation, and also in mouse lymphoma L5178Y cells by means of micronucleus and comet assays. In microbes the drug was tested at concentrations up to 500 \(\mu\)g/plate and in mouse lymphoma cells up to 2,000 \(\mu\)g/ml. Results: In both test-systems in all experiments completely negative results were obtained although FS-1 was tested at maximum tolerated doses. Conclusions: The drug is not genotoxic. This is advantageous because many antibacterial/antiviral drugs possess such activity.},
  language  = {en}
}
@phdthesis{Spiegel2015,
  author    = {Spiegel, Silvana},
  title     = {Mikrokernfrequenzanalyse unter dem Einfluss von Methylphenidat und chronischem Stress bei adultem ADHS},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-139387},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {Einleitung: Methylphenidat (MPH) als Medikament der ersten Wahl bei Patienten mit einem Aufmerksamkeitsdefizit- /Hyperaktivit{\"a}tssyndrom (ADHS) ist f{\"u}r die Therapie von Kindern aber auch von Erwachsenen weit verbreitet. Weil es immer noch Sicherheitsbedenken gegen dieses Medikament gibt, wurde in der vorliegenden Studie untersucht, ob die Langzeiteinnahme von MPH unsch{\"a}dlich hinsichtlich eines zytogenetischen Effektes ist. Ein weiteres Ziel war die Beurteilung von chronischer psychosozialer Stressbelastung von Patienten im Vergleich zu Kontrollprobanden und zu beurteilen ob die Medikation einen Einfluss auf die H{\"o}he des Stresses hat. Nicht zuletzt war das dritte Ziel der Studie zu untersuchen, ob Stress selbst zu zytogenetischen Sch{\"a}den f{\"u}hrt. Material und Methoden: Lymphozyten von 72 (42 ADHS- und 28 gesunde Kontrollprobanden) geschlechts- und altersgematchte Probanden im Alter von 18-28 Jahren, wurden aus ven{\"o}sem Blut f{\"u}r den Mikronukleusassay isoliert. Hauptendpunkt der Studie war die Mikrokernanzahl in binukle{\"a}ren Zellen. Die psychosoziale Stressbelastung der letzten drei Monate wurde mit dem Trier Inventar zum chronischen Stress (TICS) gemessen. Zus{\"a}tzlich wurden Speichelproben f{\"u}r eine Cortisolmessung gesammelt. Ergebnisse: Ein Einfluss der MPH-Einnahme auf die Mikrokernfrequenz konnte nicht gefunden. ADHS-Patienten wiesen eine signifikant h{\"o}here Stressbelastung im Vergleich zu den Kontrollprobanden auf. Ein signifikanter positiver Einfluss auf das chronische Stresserleben unter MPH-Einnahme konnte bei Einnahme von mehr als 1 Jahr beobachtet werden. Die Stressbelastung der ADHS-Patienten und Kontrollprobanden zeigte keine Korrelation zu zytogenetischen Endpunkten. Eine kleine Untergruppe, ADHS-Patienten mit Komorbidit{\"a}t Depression, zeigte jedoch signifikante erh{\"o}hte Mikrokernfrequenzanzahlen unter stark erh{\"o}htem chronischen Stress. Aussichten: Aus unserer Sicht kann MPH auch in der Langzeittherapie sicher hinsichtlich eines Krebsrisikos in gewichts- und symptomadaptierter Dosis eingesetzt werden. Weitere Studien sind n{\"o}tig um das Krebsrisiko bei chronischer erh{\"o}hter Stressbelastung abzusch{\"a}tzen.},
  subject      = {ADHS},
  language  = {de}
}
@article{FedericoRedentiSturleseetal.2015,
  author    = {Federico, Stephanie and Redenti, Sara and Sturlese, Mattia and Ciancetta, Antonella and Kachler, Sonja and Klotz, Karl-Norbert and Cacciari, Barbara and Moro, Stefano and Spalluto, Giampiero},
  title     = {The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives},
  series = {PLoS One},
  volume    = {10},
  journal   = {PLoS One},
  number    = {12},
  doi       = {10.1371/journal.pone.0143504},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-137133},
  pages     = {e0143504},
  year      = {2015},
  abstract  = {A new series of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine (PTP) derivatives has been developed in order to explore their affinity and selectivity profile at the four adenosine receptor subtypes. In particular, the PTP scaffold was conjugated at the C2 position with the 1-(3-trifluoromethyl-benzyl)-1H-pyrazole, a group believed to confer potency and selectivity toward the human (h) A\(_{2B}\) adenosine receptor (AR) to the xanthine ligand 8-(1-(3-(trifluoromethyl) benzyl)-1H-pyrazol-4-yl)-1,3-dimethyl-1H-purine-2,6(3H, 7H)-dione (CVT 6975). Interestingly, the synthesized compounds turned out to be inactive at the hA\(_{2B}\) AR but they displayed affinity at the hA\(_3\) AR in the nanomolar range. The best compound of the series (6) shows both high affinity (hA\(_3\) AR K\(_i\) = 11 nM) and selectivity (A\(_1\)/A\(_3\) and A\(_{2A}\)/A\(_3\) > 9090; A\(_{2B}\)/A\(_3\) > 909) at the hA\(_3\) AR. To better rationalize these results, a molecular docking study on the four AR subtypes was performed for all the synthesized compounds. In addition, CTV 6975 and two close analogues have been subjected to the same molecular docking protocol to investigate the role of the 1-(3-trifluoromethyl-benzyl)-1H-pyrazole on the binding at the four ARs.},
  language  = {en}
}
@phdthesis{Leyh2015,
  author    = {Leyh, Annekathrin},
  title     = {In vitro Untersuchungen zur Genotoxizit{\"a}t von Insulin},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-131986},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {Insulin ist ein essentielles Hormon im menschlichen K{\"o}rper, welches f{\"u}r die Senkung der Blutglukosekonzentration, die Bildung von Energiespeichern und das Zellwachstum verantwortlich ist. Eine mit der Fehlregulation der Insulinproduktion einhergehenden Krankheit ist der Diabetes mellitus. F{\"u}r diese Arbeit spielt der Typ 2 dieser Erkrankung eine wichtige Rolle. Es entwickelt sich bei Patienten mit diesem Typ des Diabetes mellitus langsam eine Insulinresistenz, die zun{\"a}chst durch eine kompensatorische {\"U}berproduktion von Insulin charakterisiert ist. Dieser Zustand der Hyperinsulin{\"a}mie kann Jahre bis Jahrzehnte andauern, ehe es zu einem Versagen der ß-Zellen des Pankreas und somit zu einer Hypoinsulin{\"a}mie kommt. In dieser Arbeit war es Ziel herauszufinden, ob diese lange Zeit herrschende Hyperinsulin{\"a}mie einen Einfluss auf die menschliche DNA hat. Die Genotoxizit{\"a}t von hohen Insulinkonzentrationen wurde in Hep-G2 Zellen, HT29 Zellen, sowie prim{\"a}ren humanen peripheren Lymphozyten mithilfe des Comet Assays und des Mikrokerntests nachgewiesen. Oxidativer Stress bzw. dessen Reduzierung durch Antioxidantien und Inhibitoren wurde in HT29 Zellen mithilfe der DHE-F{\"a}rbung detektiert. Diese Arbeit belegt dass sich Insulin sch{\"a}digend auf das menschliche Genom in vitro auswirken kann. Eine besondere Relevanz haben die durchgef{\"u}hrten Experimente mit prim{\"a}ren menschlichen Lymphozyten. Denn bei ihnen handelt es sich um Zellen, die im Gegensatz zu der auch genutzten humanen Leberkarzinomzelllinie Hep-G2 und der humanen Kolonkarzinomzelllinie HT29 nicht transformiert sind. Eine weitere wesentliche Erkenntnis dieser Arbeit ist, dass schon pathophysiologisch vorliegende Insulinkonzentrationen in der Lage sind Genomsch{\"a}digungen in vitro zu induzieren. HT29 Zellen zeigten bei Kurzzeitbehandlung mit nur 1nM Insulin eine signifikante Erh{\"o}hung der DNA-Sch{\"a}digung. Bei Langzeitexposition von 6 Tagen konnten schon 0,5nM signifikante DNA-Sch{\"a}den hervorrufen. Diese durch Insulin hervorgerufenen Sch{\"a}den k{\"o}nnten, falls sie so auch in vivo entstehen, bei Versagen von Reparaturmechanismen zur Entstehung von Mutationen und sich daraus entwickelnden Karzinomen beitragen. Aus diesem Grund war ein weiteres Ziel dieser Arbeit herauszufinden, ob bestimmte Antioxidantien oder Inhibitoren in der Lage sind die Insulin-induzierten Genomsch{\"a}digungen zu verringern. Hierf{\"u}r wurde Tempol, Apocynin, Plumbagin, VAS2870, Rotenone, PPP, HNMPA-(AM)3 und Wortmannin genutzt. Tats{\"a}chlich sind diese Substanzen in der Lage die durch Insulin hervorgerufene Sch{\"a}digung zu reduzieren. Die positiven Ergebnisse dieser Arbeit k{\"o}nnten einen ersten Hinweis auf eine m{\"o}gliche pharmakologische Intervention bei Hyperinsulin{\"a}mie mit dem Ziel der Senkung des erh{\"o}hten Krebsrisikos geben. Eine wichtige Erkenntnis aus den Ergebnissen meiner Arbeit ist, dass die Reduzierung des oxidativen Stresses eine Reduzierung der Genomsch{\"a}digung bewirkt. Die genutzten Substanzen Apocynin, Tempol, VAS2870 und Rotenone bewirkten in HT29 Zellen eine signifikante Reduzierung des durch Insulin ausgel{\"o}sten oxidativen Stresses. Um aber genauere Aussagen {\"u}ber M{\"o}glichkeiten der Therapie bei Hyperinsulin{\"a}mie zu treffen, sollten Folgestudien auch in vivo folgen, welche die in dieser Arbeit beschriebenen Effekte best{\"a}tigen.},
  subject      = {Insulin},
  language  = {de}
}
@phdthesis{ZinkgebSondergeld2015,
  author    = {Zink [geb. Sondergeld], Thomas Gerd},
  title     = {Der Cofilin-Signalweg im Glioblastoma multiforme - Ursachen f{\"u}r den Verlust von Chronophin und Einfluss von LIM-Kinase-Inhibitoren},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-127065},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {Das invasive Potential maligner Gliome beeinflusst maßgeblich die schlechte Prognose dieser Tumorentit{\"a}t. Migration und Invasion von Tumorzellen werden entscheidend durch die Cofilin-vermittelte Umstrukturierung des Aktin-Zytoskeletts gepr{\"a}gt, die durch die Aktivit{\"a}t antagonistischer Cofilin-Kinasen und -Phosphatasen reguliert wird. Im Rahmen der vorliegenden Arbeit konnte ein progressiver Expressionsverlust der Cofilin-Phosphatase Chronophin mit ansteigendem Malignit{\"a}tsgrad astrozyt{\"a}rer Gliome aufgezeigt werden, der mit einer Zunahme der Phosphorylierung von Cofilin einhergeht. In den entsprechenden Gewebeproben gelang gleichzeitig der Nachweis einer gesteigerten Expression der Cofilin-Kinase LIMK-2. Genetische und epigenetische Analysen des Chronophin-Locus konnten eine Hypermethylierung im Bereich der Promotorregion der Phosphatase identifizieren, die m{\"o}glicherweise dem Verlust von Chronophin in Glioblastom-Gewebeproben zugrunde liegt. In Glioblastom-Zelllinien, die unterschiedliche Expressionsmuster von Chronophin aufwiesen, konnten hingegen keine molekularen Alterationen festgestellt werden. Untersuchungen des Einflusses von ROCK- und LIMK-Inhibitoren auf Glioblastomzellen konnten ausgepr{\"a}gte Ver{\"a}nderungen der Zellmorphologie dokumentieren, wobei erstmals die Induktion eines stellate cell-Ph{\"a}notyps unter Einfluss des LIMK-Inhibitors BMS-5 beschrieben wird. W{\"a}hrend ROCK- und LIMK-Inhibitoren keinen Einfluss auf die 2D-Motilit{\"a}t der Tumorzellen hatten, wiesen die Glioblastomzellen in Abh{\"a}ngigkeit ihrer basalen Cofilin-Aktivit{\"a}t eine verst{\"a}rkte bzw. verminderte 3D-Invasivit{\"a}t auf. Die Erkenntnisse dieser Arbeit unterstreichen die Bedeutung des Cofilin-Signalweges f{\"u}r die Migration und Invasion von Gliomzellen, zeigen neue Angriffspunkte in der Therapie maligner Gliome auf und warnen zugleich vor einem unkritischen Einsatz neuer Wirkstoffe.},
  subject      = {Cofilin},
  language  = {de}
}
@phdthesis{Stumpf2015,
  author    = {Stumpf, Anette D.},
  title     = {Development of fluorescent FRET receptor sensors for investigation of conformational changes in adenosine A1 and A2A receptors},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125469},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {Adenosine receptors that belong to the rhodopsin-like G protein-coupled receptors (GPCRs) are involved in a lot of regulatory processes and are widely distributed throughout the body which makes them an attractive target for drugs. However, pharmacological knowledge of these receptors is still limited. A big advance regarding the structural knowledge of adenosine receptors was the development of the first crystal structure of the adenosine A2A receptor in 2008. The crystal structure revealed the amino acids that form the ligand binding pocket of the receptor and depicted the endpoint of receptor movement in the ligand binding process. Within the scope of this work two members of the adenosine receptor family were investigated, namely the adenosine A1 and the A2A receptor (A1R, A2AR). A1R was generated on base of the previously developed A2AR. Receptors were tagged with fluorophores, with the cyan fluorescent protein (CFP) at the C-terminal end of receptor and the Fluorescein Arsenical Hairpin binder (FlAsH) binding sequence within the third intracellular loop of receptors. Resulting fluorescent receptor sensors A1 Fl3 CFP and A2A Fl3 CFP were investigated with help of Fluorescence Resonance Energy Transfer (FRET) measurements within living cells. FRET experiments enable the examination of alteration in the distance of two fluorophores and thus the observation of receptor dynamical movements. For comparison of A1R and A2AR regarding receptor dynamical movement upon ligand binding, fluorescent receptor sensors A1 Fl3 CFP and A2A Fl3 CFP were superfused with various ligands and the outcomes of FRET experiments were compared regarding signal height of FRET ratio evoked by the distinct ligand that is correlated to the conformational change of receptor upon ligand binding. Beside the different direction of FRET ratio upon ligand binding at A1R and A2AR sensor, there were differences observable when signal height and association and dissociation kinetics of the various ligands investigated were compared to each other. Differences between the adenosine receptor subtypes were especially remarkable for the A1R subtype selective agonist CPA and the A2AR subtype selective agonist CGS 21680. Another part of the project was to investigate the influence of single amino acids in the ligand binding process within the fluorescent A1R sensor. Amino acid positions were derived from the crystal structure of the A2AR forming the ligand binding pocket and these amino acids were mutated in the A1R structure. Investigation of the A1R sensor and its mutants regarding confocal analysis showed involvement of some amino acids in receptor localization. When these amino acids were mutated receptors were not expressed in the plasma membrane of cells. Some amino acids investigated were found to be involved in the ligand binding process in general whereas other amino acids were found to have an influence on the binding of distinct structural groups of the ligands investigated. In a further step, A1R and A2AR were N-terminally tagged with SNAP or CLIP which allowed to label receptor sensors with multiple fluorophores. With this technique receptor distribution in cells could be investigated with help of confocal analysis. Furthermore, ligand binding with fluorescent adenosine receptor ligands and their competition with help of a non-fluorescent antagonist was examined at the SNAP tagged A1R and A2AR. Finally the previously developed receptor sensors were combined to the triple labeled receptor sensors SNAP A1 Fl3 CFP and SNAP A2A Fl3 CFP which were functional regarding FRET experiments and plasma membrane expression was confirmed via confocal analysis. In the future, with the help of this technique, interaction between fluorescent ligand and SNAP tagged receptor can be monitored simultaneously with the receptor movement that is indicated by the distance alteration between FlAsH and CFP. This can lead to a better understanding of receptor function and its dynamical movement upon ligand binding which may contribute to the development of new and more specific drugs for the A1R and A2AR in the future.},
  subject      = {Adenosinrezeptor},
  language  = {en}
}
@article{BoivinBeyersdorfPalmetal.2015,
  author    = {Boivin, Val{\´e}rie and Beyersdorf, Niklas and Palm, Dieter and Nikolaev, Viacheslav O. and Schlipp, Angela and M{\"u}ller, Justus and Schmidt, Doris and Kocoski, Vladimir and Kerkau, Thomas and H{\"u}nig, Thomas and Ertl, Georg and Lohse, Martin J. and Jahns, Roland},
  title     = {Novel Receptor-Derived Cyclopeptides to Treat Heart Failure Caused by \(Anti-β_1-Adrenoceptor\) Antibodies in a Human-Analogous Rat Model},
  series = {PLoS One},
  volume    = {10},
  journal   = {PLoS One},
  number    = {2},
  doi       = {10.1371/journal.pone.0117589},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-126028},
  pages     = {e0117589},
  year      = {2015},
  abstract  = {Despite recent therapeutic advances the prognosis of heart failure remains poor. Recent research suggests that heart failure is a heterogeneous syndrome and that many patients have stimulating auto-antibodies directed against the second extracellular loop of the \(β_1\) adrenergic receptor \((β_1EC2)\). In a human-analogous rat model such antibodies cause myocyte damage and heart failure. Here we used this model to test a novel antibody-directed strategy aiming to prevent and/or treat antibody-induced cardiomyopathy. To generate heart failure, we immunised n = 76/114 rats with a fusion protein containing the human β1EC2 (amino-acids 195-225) every 4 weeks; n = 38/114 rats were control-injected with 0.9\% NaCl. Intravenous application of a novel cyclic peptide mimicking \(β_1EC2\) (\(β_1EC2-CP\), 1.0 mg/kg every 4 weeks) or administration of the \(β_1-blocker\) bisoprolol (15 mg/kg/day orally) was initiated either 6 weeks (cardiac function still normal, prevention-study, n = 24 (16 treated vs. 8 untreated)) or 8.5 months after the 1st immunisation (onset of cardiomyopathy, therapy-study, n = 52 (40 treated vs. 12 untreated)); n = 8/52 rats from the therapy-study received \(β_1EC2-CP/bisoprolol\) co-treatment. We found that \(β_1EC2-CP\) prevented and (alone or as add-on drug) treated antibody-induced cardiac damage in the rat, and that its efficacy was superior to mono-treatment with bisoprolol, a standard drug in heart failure. While bisoprolol mono-therapy was able to stop disease-progression, \(β_1EC2-CP\) mono-therapy -or as an add-on to bisoprolol- almost fully reversed antibody-induced cardiac damage. The cyclo¬peptide acted both by scavenging free \(anti-β_1EC2-antibodies\) and by targeting \(β_1EC2\)-specific memory B-cells involved in antibody-production. Our model provides the basis for the clinical translation of a novel double-acting therapeutic strategy that scavenges harmful \(anti-β_1EC2-antibodies\) and also selectively depletes memory B-cells involved in the production of such antibodies. Treatment with immuno-modulating cyclopeptides alone or as an add-on to \(β_1\)-blockade represents a promising new therapeutic option in immune-mediated heart failure.},
  language  = {en}
}
@phdthesis{Bellwon2015,
  author    = {Bellwon, Patricia},
  title     = {Kinetic assessment by in vitro approaches - A contribution to reduce animals in toxicity testing},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-122693},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {The adoption of directives and regulations by the EU requires the development of alternative testing strategies as opposed to animal testing for risk assessment of xenobiotics. Additionally, high attrition rates of drugs late in the discovery phase demand improvement of current test batteries applied in the preclinical phase within the pharmaceutical area. These issues were taken up by the EU founded 7th Framework Program "Predict-IV"; with the overall goal to improve the predictability of safety of an investigational product, after repeated exposure, by integration of "omics" technologies applied on well established in vitro approaches. Three major target organs for drug-induced toxicity were in focus: liver, kidney and central nervous system. To relate obtained dynamic data with the in vivo situation, kinetics of the test compounds have to be evaluated and extrapolated by physiologically based pharmacokinetic modeling. This thesis assessed in vitro kinetics of the selected test compounds (cyclosporine A, adefovir dipivoxil and cisplatinum) regarding their reliability and relevance to respective in vivo pharmacokinetics. Cells were exposed daily or every other day to the test compounds at two concentration levels (toxic and non-toxic) for up to 14 days. Concentrations of the test compounds or their major biotransformation products were determined by LC-MS/MS or ICP-MS in vehicle, media, cells and plastic adsorption samples generated at five different time-points on the first and the last treatment day. Cyclosporine A bioaccumulation was evident in primary rat hepatocytes (PRH) at the high concentration, while efficient biotransformation mediated by CYP3A4 and CYP3A5 was determined in primary human hepatocytes (PHH) and HepaRG cells. The lower biotransformation in PRH is in accordance with observation made in vivo with the rat being a poor model for CYP3A biotransformation. Further, inter-assay variability was noticed in PHH caused by biological variability in CYP3A4 and CYP3A5 activity in human donors. The inter-assay variability observed for PRH and HepaRG cells was a result of differences between vehicles regarding their cyclosporine A content. Cyclosporine A biotransformation was more prominent in HepaRG cells due to stable and high CYP3A4 and CYP3A5 activity. In addition, in vitro clearances were calculated and scaled to in vivo. All scaled in vitro clearances were overestimated (PRH: 10-fold, PHH: 2-fold, HepaRG cells: 2-fold). These results should be proven by physiologically-based pharmacokinetic modeling and additional experiments, in order to verify that these overestimations are constant for each system and subsequently can be diminished by implementation of further scaling factors. Brain cell cultures, primary neuronal culture of mouse cortex cells and primary aggregating rat brain cells, revealed fast achieved steady state levels of cyclosporine A. This indicates a chemical distribution of cyclosporine A between the aqueous and organic phases and only minor involvement of biological processes such as active transport and biotransformation. Hence, cyclosporine A uptake into cells is presumably transport mediated, supported by findings of transporter experiments performed on a parallel artificial membrane and Caco-2 cells. Plastic adsorption of cyclosporine A was significant, but different for each model, and should be considered by physiologically based pharmacokinetic modeling. Kinetics of adefovir dipivoxil highlights the limits of in vitro approaches. Active transporters are required for adefovir uptake, but were not functional in RPTECT/TERT1. Therefore, adefovir uptake was limited to passive diffusion of adefovir dipivoxil, which itself degrades time-dependently under culture conditions. Cisplatinum kinetics, studied in RPTEC/TERT1 cells, indicated intracellular enrichment of platinum, while significant bioaccumulation was not noted. This could be due to cisplatinum not reaching steady state levels within 14 days repeated exposure. As shown in vivo, active transport occurred from the basolateral to apical side, but with lower velocity. Hence, obtained data need to be modeled to estimate cellular processes, which can be scaled and compared to in vivo. Repeated daily exposure to two different drug concentrations makes it possible to account for bioaccumulation at toxic concentrations or biotransformation/extrusion at non-toxic concentrations. Potential errors leading to misinterpretation of data were reduced by analyses of the vehicles as the applied drug concentrations do not necessarily correspond to the nominal concentrations. Finally, analyses of separate compartments (medium, cells, plastic) give insights into a compound's distribution, reduce misprediction of cellular processes, e.g. biotransformation, and help to interpret kinetic data. On the other hand, the limits of in vitro approaches have also been pointed out. For correct extrapolation to in vivo, it is essential that the studied in vitro system exhibits the functionality of proteins, which play a key role in the specific drug induced toxicity. Considering the benefits and limitations, it is worth to validate this long-term treatment experimental set-up and expand it on co-culture systems and on organs-on-chips with regard to alternative toxicity testing strategies for repeated dose toxicity studies.},
  subject      = {Zellkultur},
  language  = {en}
}